STAAR Surgical at William Blair Conference: Strategic Shifts Amid Challenges

At the William Blair Growth Stock Conference, STAAR Surgical (STAA) CEO Steve Farrell addressed the company's strategic shift towards converting glasses and contacts wearers to surgical solutions amid a challenging financial backdrop. STAAR experienced a 3% revenue decline in 2024, attributed to headwinds in the China market, though ex-China sales grew 9% in Q1 2024. While working to mitigate tariffs and reduce SG&A expenses to a $225 million run rate, STAAR anticipates a sales rebound in China and globally in Q3, driven by regulatory approvals and a growing market opportunity due to increasing myopia prevalence.

Analysis

STAAR Surgical (STAA) presented a strategy focused on navigating recent financial difficulties and capturing long-term growth, as detailed at the William Blair Growth Stock Conference. The company reported a 3% revenue decline in 2024 to $313.9 million, predominantly due to a downturn in the China market, which constitutes 51% of its sales. This weakness persisted into early 2025, with Q1 net sales falling to $42.6 million from $77.4 million year-over-year, and gross margins contracting to 65.8% from 78.9% due to reduced production and inventory adjustments. Despite these challenges, STAAR highlighted a 9% year-over-year sales growth ex-China in Q1 2025, demonstrating resilience in other markets. Management is actively addressing these issues by aiming to resolve China inventory excesses by the end of June 2025, reducing SG&A expenses towards a $225 million annual run-rate (incurring $22.7 million in Q1 restructuring charges), and utilizing its Swiss manufacturing facility to mitigate tariff impacts. CEO Steve Farrell projects a significant sales rebound in Q3 2025, driven by recoveries in China and globally, recent regulatory approvals in key Asian and South American markets, and the planned limited rollout of EVO Plus/V5 in China in Q4. The company is also strategically broadening its target market to include glasses and contact lens wearers, citing the increasing global prevalence of myopia as a substantial long-term opportunity. While abstaining from short-term guidance due to market volatility, STAAR aims to return to historical profitability, leveraging its EVO ICL technology's competitive advantages.

Key Decisions for Investors

• Investors should closely monitor STAAR's execution on its articulated turnaround strategy, particularly the normalization of China sales in Q3 2025, achievement of the targeted $225 million SG&A run-rate, and recovery of gross margins.
• The long-term thesis depends on the company's ability to successfully penetrate the larger market of glasses and contact lens wearers and capitalize on favorable myopia trends; however, the lack of formal guidance introduces near-term uncertainty.
• Consider the balance between the CEO's optimistic outlook for a second-half recovery and the significant Q1 2025 downturn, recognizing that a substantial improvement in China and stable ex-China growth are critical for validating the recovery narrative.